<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077384</url>
  </required_header>
  <id_info>
    <org_study_id>2020-012-00JP1</org_study_id>
    <nct_id>NCT05077384</nct_id>
  </id_info>
  <brief_title>Open-label Study of Surufatinib in Japanese Patients</brief_title>
  <official_title>An Open-Label Study of Surufatinib in Japanese Patients With Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2, open-label, multi-centre study of surufatinib in patients with&#xD;
      unresectable, locally advanced, or recurrent nonhematologic malignancies who do not respond&#xD;
      or are intolerant to standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the tolerability and efficacy of surufatinib in&#xD;
      Japanese patients.&#xD;
&#xD;
      The study will be conducted in 2 parts:&#xD;
&#xD;
        -  Part 1 - evaluation of tolerability and safety of surufatinib and confirmation of the&#xD;
           recommended clinical dose in Japanese patients with nonhematologic malignancies&#xD;
&#xD;
        -  Part 2 - evaluation of antitumor activity and confirmation of tolerability of&#xD;
           surufatinib in Japanese patients with NETs&#xD;
&#xD;
      All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days&#xD;
      starting on Cycle 1 Day 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">May 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Incidence of treatment-emergent adverse events (TEAEs) graded by the Investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0).</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>To evaluate surufatinib-related adverse events in patients with NETs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Objective response rate. This will be assessed on the proportion of participants with partial response or complete response as determined by the Investigator based on RECIST v1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The primary outcome of part 2 will be objective response rate in patients with NETs when treated with surufatinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentrations of surufatinib which will be assessed by the Cmax, tmax, AUC, Cmin and CL/F</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Blood sampling will be taken to measure levels of the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) which is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator based on RECIST v1.1, or death from any cause, whichever occurs first</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The duration between the enrollment date and the first disease progression (PD) or death (whichever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) which will be defined as the time from the first response to disease progression documented after treatment initiation or death, whichever occurs first. DOR will include CR, CR plus CRi, overall response (OR), and CR plus CRh.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Non-hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Surufatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib</intervention_name>
    <description>Surufatinib 300 mg oral once daily</description>
    <arm_group_label>Surufatinib</arm_group_label>
    <other_name>HMPL-012</other_name>
    <other_name>sulfatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically documented disease as follows:&#xD;
&#xD;
               1. Part 1: unresectable, locally advanced or metastatic nonhematologic malignancy&#xD;
                  that is relapsed/refractory to or intolerant of established therapies known to&#xD;
                  provide clinical benefit&#xD;
&#xD;
               2. Part 2: locally advanced or metastatic, low (grade 1) or intermediate (grade 2)&#xD;
                  grade NETs that have been previously treated with at least 1 line of systemic&#xD;
                  therapy&#xD;
&#xD;
          2. Has radiologic evidence of progressive tumour within 12 months of study enrolment&#xD;
&#xD;
          3. Is willing and able to provide informed consent&#xD;
&#xD;
          4. Is ≥20 years of age&#xD;
&#xD;
          5. Has measurable lesions according to RECIST Version 1.1&#xD;
&#xD;
          6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          7. Female patients of childbearing potential and male patients with partners of&#xD;
             childbearing potential agree to use a highly effective form(s) of contraception&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant and lactating, or possibly pregnant.&#xD;
&#xD;
          2. Has a history of interstitial lung disease (ILD)/noninfectious pneumonitis, has&#xD;
             current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by&#xD;
             imaging at screening.&#xD;
&#xD;
          3. Known active viral hepatits&#xD;
&#xD;
          4. Has an AE due to previous anti-tumour therapy that has not recovered to ≤CTCAE Grade&#xD;
             1, except alopecia and peripheral neurotoxicity with ≤CTCAE Grade 2 caused by platinum&#xD;
             chemotherapy&#xD;
&#xD;
          5. Uncontrollable hypertension, defined as systolic blood pressure ≥140 mmHg and/or&#xD;
             diastolic blood pressure ≥90 mmHg, despite antihypertensive medication&#xD;
&#xD;
          6. Gastrointestinal disease or condition within 6 months prior to first dose&#xD;
&#xD;
          7. Has a history or presence of a serious haemorrhage (&gt;30 mL within 3 months) or&#xD;
             haemoptysis (&gt;5 mL blood within 4 weeks)&#xD;
&#xD;
          8. Clinically significant cardiovascular disease.&#xD;
&#xD;
          9. Brain metastases and/or spinal cord compression untreated with surgery and/or&#xD;
             radiotherapy, and without clinical imaging evidence of stable disease (SD) for 14 days&#xD;
             or longer; patients requiring steroids within 4 weeks prior to start of study&#xD;
             treatment will be excluded.&#xD;
&#xD;
         10. A high risk of bleeding at screening due to tumour invasion into major vessels, such&#xD;
             as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined&#xD;
             by investigators.&#xD;
&#xD;
         11. Has arterial thrombosis or deep venous thrombosis within 6 months prior to first&#xD;
             dosing, or thromboembolic events (including stroke and/or transient ischaemic attack)&#xD;
             within 12 months prior to first dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kauh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison Medipharma Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Lees, PhD</last_name>
    <phone>+61 1800559724</phone>
    <email>ausmedinfo@hutch-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Tucci</last_name>
    <email>christucci@hutch-med.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Unit</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fukuoka Sanno Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Unit</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kagawa University Hospital</name>
      <address>
        <city>Kagawa</city>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Unit</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Unit</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Mitaka</city>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Unit</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Centre</name>
      <address>
        <city>Nagoya</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansia Electric Power Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Unit</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Unit</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <zip>890-8574,</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital</name>
      <address>
        <city>Yokohama</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Unit</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

